Country: Canada
Language: English
Source: Health Canada
OZENOXACIN
FERRER INTERNACIONAL, S.A.
D06AX14
OZENOXACIN
1%
CREAM
OZENOXACIN 1%
TOPICAL
10G
Prescription
ANTIBIOTICS
Active ingredient group (AIG) number: 0159010001; AHFS:
APPROVED
2017-05-01
_OZANEX™ (ozenoxacin) Product Monograph _ _Page 1 of 24_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR OZANEX™ ozenoxacin cream 1% w/w Topical Antibiotic MANUFACTURER: Ferrer Internacional, S.A. Date of Preparation: May 1, 2017 Gran Via Carlos III, 94 08028 - Barcelona Spain IMPORTED AND DISTRIBUTED BY: Cipher Pharmaceuticals Inc. 2345 Argentia Road, Suite 100A Mississauga, Ontario L5N 8K4 Submission Control No: 192925 _ _ _OZANEX™ (ozenoxacin) Product Monograph _ _Page 2 of 24_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................5 DRUG INTERACTIONS ....................................................................................................6 DOSAGE AND ADMINISTRATION ................................................................................6 OVERDOSAGE ..................................................................................................................7 ACTION AND CLINICAL PHARMACOLOGY ..............................................................7 STORAGE AND STABILITY ............................................................................................8 DOSAGE FORMS, COMPOSITION AND PACKAGING ...............................................8 PART II: SCIENTIFIC INFORMATION .................................................................................9 PHARMACEUTICAL INFORMATION ............................................................................9 CLINICAL TRIALS .................................................................................. Read the complete document